X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9920) 9920
Book Chapter (11) 11
Magazine Article (5) 5
Book / eBook (4) 4
Conference Proceeding (3) 3
Publication (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8076) 8076
sirolimus - therapeutic use (4841) 4841
male (4371) 4371
female (4112) 4112
immunosuppressive agents - therapeutic use (3126) 3126
rapamycin (2971) 2971
middle aged (2917) 2917
sirolimus (2856) 2856
animals (2757) 2757
sirolimus - analogs & derivatives (2535) 2535
transplantation (2412) 2412
sirolimus - pharmacology (2206) 2206
treatment outcome (2184) 2184
everolimus (2072) 2072
adult (2004) 2004
aged (1957) 1957
sirolimus - administration & dosage (1929) 1929
surgery (1926) 1926
oncology (1509) 1509
immunology (1414) 1414
mice (1304) 1304
sirolimus - adverse effects (1229) 1229
cardiac & cardiovascular systems (1153) 1153
mammalian target (1144) 1144
mtor (1089) 1089
tor serine-threonine kinases - antagonists & inhibitors (1088) 1088
cancer (1060) 1060
time factors (1010) 1010
immunosuppressive agents - adverse effects (1005) 1005
stents (950) 950
cyclosporine (914) 914
follow-up studies (896) 896
drug-eluting stents (886) 886
pharmacology & pharmacy (878) 878
therapy (851) 851
antineoplastic agents - therapeutic use (830) 830
analysis (810) 810
drug therapy, combination (807) 807
care and treatment (805) 805
kidney transplantation (805) 805
immunosuppression (803) 803
tor serine-threonine kinases - metabolism (802) 802
retrospective studies (764) 764
tacrolimus (732) 732
immunosuppressive agents - administration & dosage (723) 723
risk factors (721) 721
graft rejection - prevention & control (717) 717
calcineurin inhibitors (703) 703
signal transduction - drug effects (702) 702
research (693) 693
cyclosporine - therapeutic use (655) 655
immunosuppressive agents - pharmacology (652) 652
cell line, tumor (641) 641
tor serine-threonine kinases (621) 621
rats (615) 615
health aspects (612) 612
efficacy (609) 609
prospective studies (606) 606
recipients (601) 601
kidney transplantation - immunology (577) 577
cell proliferation - drug effects (567) 567
stent (567) 567
tacrolimus - therapeutic use (563) 563
mycophenolate-mofetil (557) 557
restenosis (550) 550
expression (546) 546
abridged index medicus (535) 535
apoptosis (534) 534
kidneys (529) 529
medicine & public health (527) 527
inhibition (523) 523
disease models, animal (520) 520
signal transduction (513) 513
cell biology (506) 506
antineoplastic combined chemotherapy protocols - therapeutic use (504) 504
dose-response relationship, drug (502) 502
drug therapy (501) 501
proteins (499) 499
coronary angiography (497) 497
mycophenolic acid - analogs & derivatives (497) 497
activation (494) 494
adolescent (487) 487
thrombosis (486) 486
survival (485) 485
urology & nephrology (481) 481
mycophenolic acid - therapeutic use (474) 474
implantation (466) 466
autophagy (449) 449
hematology (446) 446
young adult (441) 441
kidney neoplasms - drug therapy (440) 440
phosphorylation (436) 436
trial (435) 435
tumors (430) 430
immunosuppressive agents (429) 429
child (428) 428
immunotherapy (427) 427
pathway (425) 425
carcinoma, renal cell - drug therapy (423) 423
sirolimus - pharmacokinetics (408) 408
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9715) 9715
French (94) 94
Japanese (58) 58
Spanish (55) 55
Chinese (51) 51
German (50) 50
Russian (18) 18
Italian (12) 12
Hungarian (10) 10
Portuguese (8) 8
Czech (7) 7
Polish (6) 6
Dutch (4) 4
Finnish (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Danish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
World journal of urology, ISSN 1433-8726, 2016, Volume 35, Issue 2, pp. 179 - 188
Journal Article
Journal of oral and maxillofacial surgery, ISSN 0278-2391, 2013, Volume 71, Issue 9, pp. 1532 - 1540
Purpose To investigate the efficacy and safety of zoledronic acid (ZA) combined with targeted therapy (TT). Materials and Methods A retrospective study was... 
Surgery | SURVIVAL | PROSTATE | ADHESION | BISPHOSPHONATES | CANCER-PATIENTS | NECROSIS | DENTISTRY, ORAL SURGERY & MEDICINE | SKELETAL-RELATED EVENTS | SUNITINIB | BREAST | PROGRESSION | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Interleukin-2 - therapeutic use | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Angiogenesis Inhibitors - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Radiography, Panoramic | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Bone Density Conservation Agents - adverse effects | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Fractures, Spontaneous - etiology | Survival Rate | Spinal Cord Compression - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Cohort Studies | Care and treatment | Trade and professional associations | Metastasis
Journal Article
Blood, ISSN 0006-4971, 08/2014, Volume 124, Issue 9, pp. 1404 - 1411
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 3, pp. 502 - 509
Abstract Background Bone metastases (BMs) are frequently present in patients with metastatic renal cell carcinoma (mRCC) and cause significant morbidity.... 
Urology | mTOR inhibitors | VEGF-targeted therapy | Renal cell carcinoma | Bisphosphonates | Bone metastases | TARGETED THERAPY | PHASE-III | POPULATION-BASED ANALYSIS | OSTEONECROSIS | ZOLEDRONIC ACID | BREAST-CANCER | US MEDICARE BENEFICIARIES | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PROGRESSION-FREE | Niacinamide - analogs & derivatives | Prognosis | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Hypocalcemia - chemically induced | Renal Insufficiency - chemically induced | Diphosphonates - therapeutic use | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Bone Density Conservation Agents - adverse effects | Interferon-alpha - therapeutic use | Bone Density Conservation Agents - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Survival Rate | Disease-Free Survival | Carcinoma, Renal Cell - secondary | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | VEGF targeted therapy
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | DOUBLE-BLIND | INTERFERON-ALPHA | AGENTS | EVEROLIMUS | ONCOLOGY | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | ORIGINAL REPORTS
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2012, Volume 39, Issue 4, pp. 388 - 401
... in progression-free survival (PFS) and overall survival (OS) of mRCC patients in recent years. This was contingent upon the use, efficacy and tolerability of several... 
Hematology, Oncology and Palliative Medicine | Side effects | Adverse events | Targeted therapy | Renal cell carcinoma | MAMMALIAN TARGET | SUNITINIB TREATMENT | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | KINASE INHIBITORS | INTERFERON-ALPHA | ONCOLOGY | RANDOMIZED PHASE-II | NASAL-SEPTUM PERFORATION | QUALITY-OF-LIFE | JAPANESE PATIENTS | FOOT SKIN REACTION | Niacinamide - analogs & derivatives | Humans | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Molecular Targeted Therapy - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Imidazoles - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | Cancer | Index Medicus
Journal Article